Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 5/20 | 0.76 |
| ▸ | MIF | P14174 | 1/20 | 0.62 |
| ▸ | GRM5 | P41594 | 12/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.56 |
| ▸ | STS | P08842 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5203672 | 0.87 | FLT3 (0.62) | FLT3MIFGRM5GSK3BSTS | |
| SCHEMBL28473100 | 0.83 | FLT3 (0.71) | FLT3MIFGRM5GSK3B | |
| SCHEMBL6953018 | 0.82 | FLT3 (0.77) | FLT3MIFGRM5GSK3B | |
| SCHEMBL8354775 | 0.82 | GRM5 (0.66) | FLT3MIFGRM5GSK3B | |
| SCHEMBL28467386 | 0.81 | FLT3 (0.61) | FLT3MIFGRM5GSK3B | |
| SCHEMBL28472530 | 0.81 | FLT3 (0.61) | FLT3MIFGRM5GSK3B | |
| SCHEMBL12595925 | 0.78 | FLT3 (0.69) | FLT3MIFGRM5GSK3BSTS | |
| SCHEMBL23259255 | 0.78 | MIF (0.65) | FLT3MIFGRM5GSK3B | |
| SCHEMBL31373412 | 0.77 | FLT3 (0.66) | FLT3MIFGRM5GSK3B | |
| SCHEMBL29158520 | 0.77 | FLT3 (1.00) | FLT3MIFGRM5GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458708-B1 | HETEROARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2007-09-26 | — | — | EP | claimed |
| US-7105548-B2 | Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 | MERCK & CO., INC. (US) | 2006-09-12 | — | — | US | claimed |
| EP-1458708-A4 | HETEROARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2005-11-16 | — | — | EP | claimed |
| US-20050020585-A1 | Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2005-01-27 | — | — | US | claimed |
| EP-1458708-A2 | HETEROARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2004-09-22 | — | — | EP | claimed |
| WO-2004030637-A2 | TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE | MERCK & CO., INC. (US) | 2004-04-15 | — | — | WO | claimed |
| WO-2003051315-A2 | HETEROARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2003-06-26 | — | — | WO | claimed |
| US-20110160208-A1 | DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20110160208-A1 | DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-30 | — | — | US | disclosed |
| US-7902369-B2 | Diaryl-substituted five-membered heterocycle derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| US-7902369-B2 | Diaryl-substituted five-membered heterocycle derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| EP-1458708-B1 | HETEROARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070173507-A1 | Dairyl-substituted five-membered heterocycle derivative | MSD K.K. (JP) | 2007-07-26 | — | — | US | disclosed |
| US-20070173507-A1 | Dairyl-substituted five-membered heterocycle derivative | MSD K.K. (JP) | 2007-07-26 | — | — | US | disclosed |
| US-7105548-B2 | Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 | MERCK & CO., INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-20050020585-A1 | Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160208-A1 | DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE | OPRK1, GRM1, GRIK1 | FLT3 855/4885MIF 4147/4885GRM5 12/4885 |
| US-20070173507-A1 | Dairyl-substituted five-membered heterocycle derivative | OPRK1, OPRL1, GRM1 | FLT3 1292/4885MIF 4247/4885GRM5 10/4885 |
| US-20050020585-A1 | Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GRIN3A | FLT3 1694/4885MIF 3844/4885GRM5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.